Mary Duseau

Feb 05, 2015

Roka Bioscience has appointed Mary Duseau senior vice president and chief commercial officer. She will report to the firm's President and CEO Paul Thomas. Duseau has more than 25 years of experience in sales and marketing and was most recently the global sales director at Andor Technologies, a division of Oxford Instruments. Before that, she was at PerkinElmer between 2000 and 2012 where she held various sales and management positions.

Breaking News

Plasmid Transfer Let Cholera Pathogen in Yemen Become Multidrug Resistant, Study Suggests
Harbinger Health Raises $140 Million in Series B Financing
BioMérieux's BioFire Defense Secures $18.8M US DoD Contract for Infectious Disease Testing
Biora Therapeutics Settles Claims of Misleading Genetic Testing Advertisements
Genetic Overlap Between Schizophrenia, Cardiovascular Disease Risk Uncovered by GWAS Analysis

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.